Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS (MITOTARGET)
Phase II/III, Multicenter, Randomized, Parallel Group, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole
Sponsor: European Commission
Listed as NCT00868166, this PHASE3 trial focuses on Amyotrophic Lateral Sclerosis and remains completed. Sponsored by European Commission, it has been updated 8 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Mar 2019 — Mar 2020 [monthly]
Completed PHASE3
Phase: PHASE2_PHASE3 → PHASE3
-
Jun 2018 — Mar 2019 [monthly]
Completed PHASE2_PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
First recorded
Apr 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- European Commission
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Berlin, Germany , Bron, France , Halle, Germany , Hanover, Germany , Leuven, Belgium , Lille, France , Limoges, France , London, United Kingdom , Madrid, Spain , Marseille, France and 5 more locations